RxDoctor Payments Data

Michelle Chalico, NP

Family · Hemet, CANPI 1396528600

Payments from drug & device makers

$3,561in general payments, 2019–2025

Across 28 payments — averaging $127.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • AbbVie$128
  • Collegium Pharmaceutical, Inc.$57
  • Curonix LLC$19
  • Exact Sciences$17
  • Forte Bio-pharma LLC$16
  • plus $14 from 1 others

What the payments were for

  • Travel & lodging$2,69076%
  • Food & beverage$87124%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific15$3,309
AbbVie6$128
Collegium Pharmaceutical, Inc.3$57
Curonix LLC1$19
Exact Sciences1$17
Forte Bio-pharma LLC1$16
Valinor Pharma, LLC1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,561 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$105,645
Medicare patients
210
Services billed
1,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl81$72,996
Buprenorphine133$33,398
Nurtec OdtRimegepant Sulfate16$29,788
MovantikNaloxegol Oxalate71$28,261
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen880$23,638
Diclofenac Sodium244$21,848
ZtlidoLidocaine29$15,674
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen430$14,976
OxycontinOxycodone Hcl27$11,999
Lidocaine116$11,639
SymproicNaldemedine Tosylate25$11,239
ButransBuprenorphine20$5,671
Gabapentin442$4,638
Morphine Sulfate ErMorphine Sulfate172$4,447
Naloxone Hcl45$2,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$57$72,99681 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →